

PHARMACY CORNER

Drug Approved for First-Line Head and Neck Cancer



Cetuximab (Erbix®) has been approved by the U.S. Food and Drug Administration (FDA) in combination with standard chemotherapy (a platinum plus 5-fluorouracil) for first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Cetuximab, a chimeric monoclonal antibody, targets and inhibits the activity of epidermal growth factor receptors (EGFRs). EGFRs commonly are overexpressed in tumor cells such as those found in SCCHN, and although cetuximab is not given as a cytotoxic chemotherapy agent, its benefits are seen in the inhibition of tumor cell proliferation.

Approval was based on the results of the Erbix in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer (EXTREME) trial. The phase III trial (N = 442) demonstrated improvements in overall survival (OS) by 37% ($p = 0.034$) and progression-free survival (PFS) by 67% ($p < 0.001$) when cetuximab was added to standard chemotherapy. Patients in the cetuximab arm ($n = 222$) experienced an OS of 10.1 months compared to 7.4 months with the chemotherapy-alone arm ($n = 220$). PFS was 5.5 months with cetuximab versus 3.3 months without.

The chemotherapy regimen used in both arms of EXTREME gave physicians the option of administering either carboplatin (AUC 5) or cisplatin (100 mg/m²) as platinum agents via IV on day 1, along with 5-fluorouracil (1,000 mg/m² per day) given as a continuous infusion during days 1 through 4.

Cetuximab also is approved as first-line therapy in combination with radiation therapy for nonmetastatic head and neck cancer. For more information, visit www.fda.gov/AboutFDA/CentersOfices/CDER/ucm278957.htm.

Trastuzumab May Work Subcutaneously

Research is ongoing regarding the possibility of making trastuzumab (Her-



ceptin®) available as a subcutaneous injection. Trastuzumab, a monoclonal antibody, has been a game-changer since its initial approval in 1998 by providing a targeted strategy for treating breast cancers that overexpressed HER2 receptors. Currently, trastuzumab is available only as a 30-minute IV infusion.

Halozyne Therapeutics, Inc. has developed a subcutaneous formulation of trastuzumab, and the Roche-funded phase III HannaH trial (N = 596) compared the safety and efficacy of traditional IV trastuzumab versus the Halozyne-developed subcutaneous product. According to Halozyne, results were comparable. One proposed advantage of subcutaneous administration is reduced administration time (about five minutes compared to a 30-minute IV infusion). For more information, visit <http://bit.ly/tjkATH>.

NOTEWORTHY

Study Reaffirms Links Between Alcohol and Breast Cancer

A study by Chen, Rosner, Hankinson, Colditz, and Willett (2011) confirmed prior studies linking alcohol to breast cancer. The authors noted that moderate alcohol consumption over a lifetime moderately increases the risk for invasive breast cancer. The authors cited data from the Nurses Health Study that examined the relationship of alcohol consumption and the occurrence of invasive breast cancer among female nurses (N = 105,986) from 1980–2008. By the study's end, 7,690 cases of invasive breast cancer were diagnosed, and data from this observational study indicated a growing risk as alcohol consumption increased.

The authors did not note that the type of alcoholic beverage made a difference; rather, it was the quantity that mattered. Relative risk increased about 10% for every 10 grams of average daily intake of alcohol. For those drinking, on average, only three to six drinks a week, the risk for invasive breast cancer increased 15%.

Typically, the standard alcoholic beverage serving has about 14 grams of alcohol, with a 12-ounce beer, a 5-ounce

glass of wine, and 1.5 ounces of 80-proof liquor containing roughly the same amount of alcohol. One of the reasons alcohol is believed to increase breast cancer risk is that alcohol consumption stimulates the production of estrogen—a key hormone in many breast cancers.

Chen, W.Y., Rosner, B., Hankinson, S.E., Colditz, G.A., & Willett, W.C. (2011). Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. *JAMA*, 306, 1884–1890. doi:10.1001/jama.2011.1590

Smokers Require More Help With Quitting

Based on the 2010 National Health Information Survey (NHIS), according to the Centers for Disease Control and Prevention (CDC), the desire of smokers to “kick the habit” is high, but methods to improve success with cessation are underused.

Smoking has been known to be extremely addictive and dangerous to one's health for decades. In addition, quitting smoking is well known to improve health symptoms and reduce fatality risk from cardiac events, strokes, and cancer. Smoking-related illness creates an unsustainable burden to the healthcare system and, combined with losses of productivity, is estimated to cost the nation \$193 billion each year. That burden, along with the recognized magnitude of lost lives from tobacco use, has motivated research directed at strategies to assist smokers to stop using tobacco products.

In the 2010 NHIS, an encouraging 69% of current adult smokers indicated a desire to quit, and about 52% had attempted to quit in the past year. That highlights, however, the addictive nature of nicotine—more than half of adult smokers attempted to quit, but failed.

As healthcare professionals with knowledge of the consequences of smoking, nurses are in a key position to assist and support smokers in cessation strategies. Somewhat surprisingly, of the 2010 NHIS participants who were smokers, only 48% reported having been advised to quit smoking by a healthcare provider in the prior year. That demonstrates an area in need of improvement. The CDC recommends that smokers be offered cessation advice